A British supermarket loyalty card holds a secret that researchers at the University of Bristol have just revealed: when women buy menstrual products, they are nearly four times more likely to reach for pain relief in that same shopping trip than on any other visit. This pattern, hidden in 211 million transactions spanning a decade, tells a story that many people experience but few institutions have bothered to measure at scale.
Dr. Victoria Sivill and her colleagues analyzed anonymized shopping data from 3.4 million customers between 2006 and 2015, looking at how menstrual pain disrupts daily life—not through surveys or clinical studies, but through the quiet language of what people actually buy. The data validated itself perfectly: the most common interval between consecutive menstrual product purchases was exactly 28 days, matching the average menstrual cycle. But the numbers also revealed something more troubling.
The study found that 26.7% of customers purchasing menstrual products also bought pain relief simultaneously. That means more than one in four women dealing with their period are seeking to manage pain at the supermarket checkout. Yet this burden is not shared equally. Customers in the lowest-income areas were 32% less likely to buy pain relief alongside menstrual products compared to those in the highest-income areas. The researchers emphasize that this gap almost certainly reflects an inability to afford over-the-counter medication rather than lower rates of menstrual pain itself—a distinction that matters enormously for policy.
What makes this research striking is not just the scale it reveals, but the invisibility it challenges. Menstrual pain is ubiquitous enough that most women experience it, yet it remains largely absent from public health conversations and scientific priorities. Co-author Dr. Anya Skatova noted the impact of seeing these numbers in aggregate: "The scale of painkiller purchases alongside menstrual products was still striking. Using shopping data, we can see just how widespread the need for pain relief really is."
The research demonstrates that smart data analysis can illuminate what clinical approaches alone might miss. Co-author Dr. James Goulding reflected on this: "It is wonderful that smart data research in the UK is able to bring issues that may have once been overlooked in scientific settings—such as the sheer scale and impact of menstrual pain—to light. This is well overdue."
The findings published in PLOS Digital Health point toward a clear next step. The authors call for "greater awareness and policy interventions to address the high prevalence of menstrual pain as well as socioeconomic dimensions of menstrual pain." They recommend that public health initiatives incorporate menstrual pain relief as part of broader efforts to improve health equity. For women in lower-income areas, this could mean ensuring affordable access to pain relief; for the health system more broadly, it means finally recognizing menstrual pain as a public health priority rather than a private problem.